Rapid Micro Biosystems Inc (RPID)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $32.65M
Last updated: Nov 17, 2026 at 11:05 AM ET
Rapid Micro Biosystems Inc (RPID) Financials: Revenue, Profit and Cash Flow
Rapid Micro Biosystems reported revenue of $33.59M for the fiscal year ended Dec 31, 2025, up 19.7% from the year before. That year, net income was -$47.12M with a net margin of -140.3%, operating cash flow was -$31.06M and free cash flow was -$31.91M. The quarter ended Jun 30, 2026 had revenue of $8.05M and net income of -$12.92M.
Revenue and Margins
Over the 15 years to Dec 2025, revenue grew from $16.08M, a compound annual rate of 5.0%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $33.59M | +19.7% | 3.1% | -141.1% | -140.3% |
| Dec 2024 | $28.05M | +24.6% | -0.4% | -178.0% | -167.2% |
| Dec 2023 | $22.52M | +31.4% | -24.4% | -251.2% | -233.0% |
| Dec 2022 | $17.13M | -26.3% | -49.8% | -369.0% | -354.9% |
| Dec 2021 | $23.23M | +44.5% | -33.3% | -203.3% | -316.5% |
| Dec 2020 | $16.08M | -2.6% | -50.2% | -190.0% | -230.6% |
| Dec 2019 | $16.51M | N/A | -1.4% | -112.9% | -128.2% |
| Dec 2011 | $10.97M | -31.8% | N/A | N/A | N/A |
| Dec 2010 | $16.08M | N/A | 0.4% | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2011 | Dec 2010 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.59M | $28.05M | $22.52M | $17.13M | $23.23M | $16.08M | $16.51M | $10.97M | $16.08M |
| Cost of revenue | $32.54M | $28.16M | $28.00M | $25.67M | $30.97M | $24.15M | $16.75M | $11.78M | $16.02M |
| Gross profit | $1.05M | -$109.00K | -$5.49M | -$8.54M | -$7.74M | -$8.07M | -$234.00K | N/A | $59.00K |
| Research and development | $13.60M | $14.60M | $12.82M | $12.87M | $9.78M | $6.53M | $5.43M | $0 | $0 |
| Operating income | -$47.39M | -$49.92M | -$56.56M | -$63.22M | -$47.23M | -$30.54M | -$18.63M | N/A | N/A |
| Net income | -$47.12M | -$46.89M | -$52.47M | -$60.81M | -$73.52M | -$37.08M | -$21.17M | N/A | N/A |
| EBITDA | -$44.25M | -$46.67M | -$53.54M | -$60.32M | N/A | -$29.08M | -$16.87M | N/A | N/A |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.05M | $8.00M | $11.28M | $7.84M | $7.26M | $7.21M | $8.22M | $7.60M | $6.62M | $5.61M | $6.34M | $6.14M |
| Gross profit | $1.21M | $371.00K | -$328.00K | $696.00K | $275.00K | $404.00K | $981.00K | $622.00K | -$189.00K | -$1.52M | -$172.00K | -$1.63M |
| Operating income | -$12.32M | -$13.85M | -$12.21M | -$11.37M | -$12.15M | -$11.66M | -$10.23M | -$12.04M | -$13.38M | -$14.27M | -$12.19M | -$14.45M |
| Net income | -$12.92M | -$14.28M | -$12.50M | -$11.51M | -$11.86M | -$11.26M | -$9.67M | -$11.32M | -$12.58M | -$13.32M | -$11.17M | -$13.39M |
Balance Sheet
As of Dec 2025, total debt of $20.20M exceeded cash and equivalents by $170.00K.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2011 | Dec 2010 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $74.85M | $98.17M | $143.45M | $190.65M | $241.17M | $70.00M | $31.69M | $1.66M | $2.32M |
| Current assets | $61.17M | $80.92M | $120.42M | $138.58M | $218.12M | $62.15M | $23.61M | N/A | N/A |
| Cash and equivalents | $20.03M | $16.91M | $24.29M | $27.06M | $178.39M | $30.08M | $12.46M | $1.00K | $156.00K |
| Total liabilities | $41.65M | $22.82M | $25.46M | $26.48M | $20.19M | $45.18M | $32.41M | $6.84M | $5.02M |
| Short-term debt | $1.30M | $1.21M | $1.13M | $766.00K | $10.58M | $6.54M | $5.35M | N/A | N/A |
| Long-term debt | $18.90M | $0 | N/A | N/A | N/A | $24.81M | $17.81M | N/A | $1.75M |
| Shareholder equity | $33.21M | $75.35M | $117.99M | $164.17M | $220.98M | -$127.01M | -$725.00K | -$5.17M | -$2.70M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $58.45M | $62.36M | $74.85M | $84.41M | $75.59M | $85.43M | $98.17M | $105.84M | $117.08M | $127.73M | $143.45M | $150.16M |
| Total liabilities | $40.70M | $41.97M | $41.65M | $40.08M | $21.04M | $19.94M | $22.82M | $21.47M | $22.50M | $21.79M | $25.46M | $22.38M |
| Cash and equivalents | $14.69M | $13.81M | $20.03M | $18.95M | $18.33M | $18.91M | $16.91M | $22.04M | $37.12M | $22.43M | $24.29M | $23.79M |
| Shareholder equity | $17.75M | $20.40M | $33.21M | $44.33M | $54.55M | $65.49M | $75.35M | $84.37M | $94.59M | $105.94M | $117.99M | $127.79M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.06M | -$44.15M | -$45.08M | -$58.55M | -$54.96M | -$31.00M | -$21.15M |
| Capital expenditures | $850.00K | $1.36M | $1.84M | $6.74M | $3.22M | $690.00K | $1.70M |
| Free cash flow | -$31.91M | -$45.52M | -$46.93M | -$65.29M | -$58.18M | -$31.69M | -$22.84M |
| Dividends paid | N/A | N/A | $186.00K | $566.00K | N/A | N/A | N/A |
| Investing cash flow | $14.33M | $36.66M | $42.15M | -$93.47M | -$13.29M | -$15.67M | -$1.70M |
| Financing cash flow | $19.77M | $203.00K | $149.00K | $693.00K | $216.75M | $64.23M | $14.87M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.70M | -$15.06M | -$3.25M | -$9.05M | -$9.70M | -$9.06M | -$9.91M | -$8.60M | -$10.12M | -$15.53M | -$9.50M | -$9.71M |
| Capital expenditures | $223.00K | $394.00K | $92.00K | $73.00K | $366.00K | $319.00K | $98.00K | $223.00K | $459.00K | $585.00K | $418.00K | $453.00K |
| Free cash flow | -$12.93M | -$15.45M | -$3.34M | -$9.12M | -$10.07M | -$9.38M | -$10.01M | -$8.82M | -$10.58M | -$16.11M | -$9.91M | -$10.16M |
Frequently Asked Questions About RPID
What is Rapid Micro Biosystems' annual revenue?
Rapid Micro Biosystems reported revenue of $33.59M for the fiscal year ended Dec 31, 2025.
How fast is Rapid Micro Biosystems' revenue growing?
Revenue was up 19.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 25.2%.
Is Rapid Micro Biosystems profitable?
No. Rapid Micro Biosystems reported net income of -$47.12M for the fiscal year ended Dec 31, 2025, with a net margin of -140.3%.
How much free cash flow does RPID generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$31.06M minus capital expenditures of $850.00K produced free cash flow of -$31.91M.
How much debt does Rapid Micro Biosystems have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $18.90M, short-term debt of $1.30M and cash and equivalents of $20.03M.
RPID pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts